

## Prescription Pharmaceutical Products<sup>1</sup>

PRODUCT*	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
<b>Oncology/Hematology</b>							
Minjuvi®	Autologous stem cell transplant (ASCT) ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	Q4-25		Q1-25	Incyte
Minjuvi®	Relapsed or refractory follicular lymphoma (FL)		Q1-26	●		●	Incyte
Pemazyre®	Unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion		Q4-25	Q2-26		Q4-25	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22			Helsinn
Aloxi® / Onicit®	Prevention of acute nausea and vomiting associated with moderate and highly emetogenic cancer chemotherapy	Q4-22	Q1-25			Q1-25	Helsinn
Trelstar®	Advanced prostate cancer	Q2-20					Debiopharm
Orgovyx®	Advanced prostate cancer	Q1-24					Sumitomo
Vidaza®	Myelodysplastic syndrome		Q2-10				BMS
Abraxane®	Metastatic adenocarcinoma of the pancreas		Q4-17				BMS
Halaven®	Metastatic breast cancer and liposarcoma subtype of soft tissue sarcoma		Q4-17	Q4-19	Q2-22		Eisai
Lenvima®	Locally advanced or metastatic differentiated thyroid cancer and previously untreated advanced or unresectable hepatocellular carcinoma		Q4-17		Q1-22		Eisai
Lenvima®	Advanced renal cell cancer		Q4-17				Eisai
<b>BGx</b>							
Ladevina® (lenalidomide)	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Own
Ladevina® (lenalidomide)	Mantle Cell Lymphoma; previously treated FL			2011			Own
Zyvalix® (abiraterone)	Metastatic castration-resistant prostate cancer			2014	Q2-18		Own
Karfib® (carfilzomib)	Relapsed or refractory multiple myeloma			Q4-19	■		Own
Leprid® (leuprolide)	Palliative treatment of advanced prostate cancer			2007			Own
Rembre® (dasatinib)	Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia; Ph+ acute lymphoblastic leukemia			2013	Q1-22		Own
Palbocil®, Bapocil® (palbociclib)	Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer			Q1-23	Q1-26		Own
Xetrane® (pomalidomide)	Multiple myeloma			Q2-19	●		Own
Xetrane® (pomalidomide)	AIDS-related Kaposi sarcoma			Q2-22			Own

<sup>1</sup> See MD&A for more details.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.

\*The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUJI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.



## Prescription Pharmaceutical Products<sup>1</sup>

PRODUCT*	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
<b>Infectious Diseases</b>							
<b>Ambisome®</b>	Invasive fungal infection		1997				Gilead
<b>Cresemba®</b>	Invasive fungal infection		Q2-20	Q3-19	Q3-19	Q2-19	Basilea
<b>Impavido®</b>	Leishmaniasis						Own
<b>BGx</b>							
<b>Dolufevir® (dolutegravir)</b>	HIV infection			Q2-21			Own
<b>Neurology</b>							
<b>Jornay PM®</b>	Attention-Deficit Hyperactivity Disorder (ADHD)	Q4-25		▲		▲	Collegium
<b>Exelon®</b>	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Own
<b>Dexedrine®</b>	ADHD	1940's					Own
<b>Xcopri®</b>	Adjunctive therapy in the management of partial-onset seizures in adults with epilepsy	Q1-24					SK
<b>Other Specialty</b>							
<b>Imvexxy®</b>	Moderate-to-severe dyspareunia	Q1-24					TXMD
<b>Myfembree®</b>	Treatment for heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women	Q1-24					Sumitomo
<b>Envarsus®PA</b>	Prophylaxis of organ rejection in allogenic kidney or liver transplant in combination with other immunosuppressants	Q2-19					Veloxis
<b>Bijuva®</b>	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24					TXMD
<b>Salofalk®</b>	Acute ulcerative colitis			2007	Pre-2019		Dr. Falk
<b>Ursofalk®</b>	Primary biliary cirrhosis			2007	Pre-2019		Dr. Falk
<b>Testim®</b>	Testosterone deficiency	2007					Endo
<b>BGx</b>							
<b>Fibridoner® (pirfenidone)</b>	Idiopathic pulmonary fibrosis			2017			Own

<sup>1</sup> See MD&A for more details.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.

\*The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUVI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.



## Pipeline and New Launches<sup>1</sup>

PRODUCT*	INDICATION OR THERAPEUTIC AREA	TERRITORY					EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	
<b>Oncology/Hematology</b>							
Minjuvi®	ASCT ineligible patients with relapsed or refractory DLBCL		Q1-24	Q4-25		Q1-25	—
Minjuvi®	Relapsed or refractory FL		Q1-26	●		●	2026-2027
Zynyz®	Squamous cell carcinoma of the anal canal Advanced Merkel cell carcinoma		▲	▲	▲	▲	2027-2029
Niktimvo®	Chronic graft-versus-host disease		●	▲		▲	2027-2029
Pemazyre®	Unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion		Q4-25	Q2-26		Q4-25	—
Tavalisse®	Previously treated for chronic immune thrombocytopenia		●	●	●	■	2026-2027
Bapocil®	Breast Cancer				Q1-26		—
Xetrane®	Multiple myeloma			Q2-19	●		2028-2029
O501	Oncology/Hematology			■			2026
O502	Oncology/Hematology			■			2026
O503	Oncology/Hematology			▲			2027
O504	Oncology/Hematology			◆			2030
O401	Oncology/Hematology		◆				2029
O402	Oncology/Hematology		◆				2029
H403	Oncology/Hematology		◆		◆		2028-2029
H402	Oncology/Hematology		◆		◆		2028-2029
<b>Neurology</b>							
Crexont®	Parkinson's disease	●	▲	●	▲	●	2027-2030
Qelbree®	ADHD	▲					2028-2029
Jornay PM®	ADHD	Q4-25		▲		▲	2028-2030
Xcopri®	Adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy	Q1-24					—
C401	Neurology				■		2026
<b>Other Specialty</b>							
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24					—
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24					—
Myfembree®	Treatment for heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women	Q1-24					—
Orgovyx®	Advanced prostate cancer	Q1-24					—
Wynzora®	Plaque psoriasis	■					2026
Gemtesa®	Treatment of overactive bladder, or OAB	▲					2028

<sup>1</sup> See MD&A for more details.

◆ Development: Products under development stage.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.

\*The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUJI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.